基于献血者实时抗体筛查估算SARS-CoV-2感染致死率
该研究在丹麦对17-69岁献血者进行SARS-CoV-2 IgM/IgG抗体检测,以估算人群血清流行率和感染致死率(IFR)。作者认为该IFR略低于此前未使用血清流行率数据的其他国家报告。
要点
- 70岁以下人群估算IFR为每10万感染者89例(95%CI 72-211)。
- 抗体血清流行率调查可用于实时监测疫情并估算IFR。
核心结论
- 丹麦全国献血者实时抗体筛查估算的SARS-CoV-2 IFR略低于此前未使用血清流行率数据的其他国家报告,且可能数倍低于当时估计值。
主要发现
- 血清流行率在不同地区之间存在差异。
- 结合现有死亡和人口数据,70岁以下感染者合并IFR估计为每10万感染者89例(95%CI 72-211)。
临床怎么用
- 可将全国献血者实时抗SARS-CoV-2血清流行率调查作为监测疫情和估算人群IFR的工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has tremendous consequences for our societies. Knowledge of the seroprevalence of SARS-CoV-2 is needed to accurately monitor the spread of the epidemic and to calculate the infection fatality rate (IFR). These measures may help the authorities make informed decisions and adjust the current societal interventions. The objective was to perform nationwide real-time seroprevalence surveying among blood donors as a tool to estimate previous SARS-CoV-2 infections and the population-based IFR. METHODS: Danish blood donors aged 17-69 years giving blood 6 April to 3 May were tested for SARS-CoV-2 immunoglobulin M and G antibodies using a commercial lateral flow test. Antibody status was compared between geographical areas, and an estimate of the IFR was calculated. Seroprevalence was adjusted for assay sensitivity and specificity taking the uncertainties of the test validation into account when reporting the 95% confidence intervals (CIs). RESULTS: The first 20 640 blood donors were tested, and a combined adjusted seroprevalence of 1.9% (95% CI, .8-2.3) was calculated. The seroprevalence differed across areas. Using available data on fatalities and population numbers, a combined IFR in patients <70 years is estimated at 89 per 100 000 (95% CI, 72-211) infections. CONCLUSIONS: The IFR was estimated to be slightly lower than previously reported from other countries not using seroprevalence data. The IFR is likely severalfold lower than the current estimate. We have initiated real-time nationwide anti-SARS-CoV-2 seroprevalence surveying of blood donations as a tool in monitoring the epidemic.
引用
- Erikstrup C, Hother CE, Pedersen OBV, et al. Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors. Clin Infect Dis. 2021. PMID: 33501969. doi:10.1093/cid/ciaa849
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。